Zai Lab (ZLAB) News Today → Three basic steps to building the Ultimate Dividend Portfolio. (From DTI) (Ad) Free ZLAB Stock Alerts $18.46 +0.54 (+3.01%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Down to $20.16Zai Lab (NASDAQ:ZLAB) Shares Gap Down to $20.16May 22, 2024 | businesswire.comZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque PsoriasisMay 21, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Down 4.4% Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.4%May 20, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up to $19.40Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $19.40May 20, 2024 | markets.businessinsider.comZai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+May 20, 2024 | businesswire.comZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in ChinaMay 19, 2024 | americanbankingnews.comInsider Selling: Zai Lab Limited (NASDAQ:ZLAB) Insider Sells $213,300.00 in StockMay 17, 2024 | insidertrades.comZai Lab Limited (NASDAQ:ZLAB) Insider Sells $213,300.00 in StockMay 17, 2024 | finance.yahoo.comInsider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells SharesMay 16, 2024 | marketbeat.comFrazor Titus Edmondson III Sells 10,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockZai Lab Limited (NASDAQ:ZLAB - Get Free Report) insider Frazor Titus Edmondson III sold 10,000 shares of Zai Lab stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $21.33, for a total value of $213,300.00. Following the completion of the transaction, the insider now owns 16,408 shares of the company's stock, valued at $349,982.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.May 16, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Down to $20.85Zai Lab (NASDAQ:ZLAB) Shares Gap Down to $20.85May 16, 2024 | finance.yahoo.comZai Lab Announces Participation in May and June Investor ConferencesMay 16, 2024 | businesswire.comZai Lab Announces Participation in May and June Investor ConferencesMay 15, 2024 | markets.businessinsider.comAnalyst Upgrades Zai Lab’s Price Objective on Strong Drug Portfolio and Growth ProspectsMay 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Zai Lab (ZLAB), Alphatec Holdings (ATEC)May 14, 2024 | businesswire.comZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaMay 13, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Trading Up 9.7%Zai Lab (NASDAQ:ZLAB) Shares Up 9.7%May 13, 2024 | marketwatch.comZai Lab Shares Rise 11% After Augtyro NDA Approved in ChinaMay 13, 2024 | stockhouse.comZai Lab Announces Approval of AUGTYRO(TM) (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPAMay 13, 2024 | markets.businessinsider.comChina Approves Zai Lab's AUGTYRO For ROS1-Positive NSCLC TreatmentMay 12, 2024 | businesswire.comZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPAMay 11, 2024 | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 10, 2024 | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketwatch.comZai Labs Shares Rise 26% After Narrower-Than-Expected 1Q LossMay 9, 2024 | marketbeat.comSegantii Capital Management Ltd Sells 101,430 Shares of Zai Lab Limited (NASDAQ:ZLAB)Segantii Capital Management Ltd trimmed its holdings in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,687,569 shares of the company's stock aMay 9, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Releases Earnings Results, Beats Estimates By $0.38 EPSZai Lab (NASDAQ:ZLAB - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.93) by $0.38. The firm had revenue of $87.15 million for the quarter, compared to analyst estimates of $77.07 million. Zai Lab had a negative return on equity of 37.07% and a negative net margin of 125.46%. During the same period last year, the company earned ($0.51) EPS.May 9, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up After Earnings BeatZai Lab (NASDAQ:ZLAB) Shares Gap Up Following Earnings BeatMay 8, 2024 | investorplace.comZLAB Stock Earnings: Zai Lab Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Zai Lab's earnings reportMay 7, 2024 | markets.businessinsider.comHere's what Wall Street expects from Zai Lab's earningsMay 2, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up to $15.90Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $15.90April 30, 2024 | finance.yahoo.comZai Lab Limited's (NASDAQ:ZLAB) Profit OutlookApril 27, 2024 | marketbeat.comVivo Capital LLC Acquires 119,521 Shares of Zai Lab Limited (NASDAQ:ZLAB)Vivo Capital LLC lifted its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 29.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 531,198 shares of the company's stocApril 25, 2024 | marketbeat.comZai Lab Limited Forecasted to Post FY2024 Earnings of ($3.50) Per Share (NASDAQ:ZLAB)Zai Lab Limited (NASDAQ:ZLAB - Free Report) - Research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for shares of Zai Lab in a report released on Tuesday, April 23rd. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($3.April 24, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Up 5.3%Zai Lab (NASDAQ:ZLAB) Shares Up 5.3%April 22, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up to $14.07Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $14.07April 21, 2024 | wsj.comZai Lab Ltd. ADRApril 19, 2024 | finance.yahoo.comZai Lab Limited (ZLAB)April 17, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Down 2.4% Zai Lab (NASDAQ:ZLAB) Trading Down 2.4%April 17, 2024 | marketbeat.comGenesis Investment Management LLP Sells 339,503 Shares of Zai Lab Limited (NASDAQ:ZLAB)Genesis Investment Management LLP trimmed its holdings in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 32.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 692,663 shares of the company's stock after selling 339,503April 16, 2024 | seekingalpha.comA Risky Bet: Zai Lab's Uncertain FutureApril 16, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Sets New 52-Week Low at $14.01Zai Lab (NASDAQ:ZLAB) Sets New 1-Year Low at $14.01April 15, 2024 | businesswire.comZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024April 15, 2024 | businesswire.comZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024April 11, 2024 | finance.yahoo.comZai Lab Statement on Executive Management Team’s Agreement on Share ActivitiesApril 11, 2024 | businesswire.comZai Lab Statement on Executive Management Team's Agreement on Share ActivitiesApril 10, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Reaches New 52-Week Low at $15.13Zai Lab (NASDAQ:ZLAB) Sets New 12-Month Low at $15.13April 9, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)April 9, 2024 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up to $15.49Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $15.49 Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Look what happened to Netflix during these “Hotspot Dates” (Ad)We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates” But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… ZLAB Media Mentions By Week ZLAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZLAB News Sentiment▼0.560.89▲Average Medical News Sentiment ZLAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZLAB Articles This Week▼54▲ZLAB Articles Average Week Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Catalyst Pharmaceuticals News Rocket Pharmaceuticals News Agios Pharmaceuticals News Amphastar Pharmaceuticals News Amneal Pharmaceuticals News Galapagos News Protagonist Therapeutics News Keros Therapeutics News Evotec News Ardelyx News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZLAB) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
